AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 3.25 |
Market Cap | 9.54M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 1.05 |
PE Ratio (ttm) | 3.03 |
Forward PE | n/a |
Analyst | Buy |
Ask | 3.37 |
Volume | 44,022 |
Avg. Volume (20D) | 41,614 |
Open | 3.46 |
Previous Close | 3.41 |
Day's Range | 3.10 - 3.46 |
52-Week Range | 3.00 - 8.98 |
Beta | undefined |
About KPRX
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, a...
Analyst Forecast
According to 1 analyst ratings, the average rating for KPRX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 214.47% from the latest price.
Next Earnings Release
Analysts project revenue of $750.00K, reflecting a n/a YoY growth and earnings per share of -0.7, making a -143.75% decrease YoY.